Your session is about to expire
← Back to Search
Transcranial Magnetic Stimulation for Autism Spectrum Disorder
N/A
Recruiting
Led By Vaughn Steele, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
For Control Group: No current or history of psychiatric disorders, other than simple phobia, and/or primary relatives with ASD
No primary relatives with history of any neurological disorder with a potentially hereditary basis, including epilepsy or MS
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during each fmri, up to 5 hours
Awards & highlights
No Placebo-Only Group
Summary
This trial is an observational study that aims to test the effect of different types of brain stimulation on how young adults with autism understand and think about other people's thoughts and feelings. The researchers want to know
Who is the study for?
This trial is for young adults with Autism Spectrum Disorder (ASD) who can undergo MRI scans and TMS sessions. It's not suitable for individuals without ASD or those who cannot safely have these procedures due to other medical conditions.
What is being tested?
The study tests if transcranial magnetic stimulation (TMS) at the right temporoparietal junction affects brain activity related to social understanding in people with autism, compared to non-autistic individuals.
What are the potential side effects?
TMS may cause discomfort at the stimulation site, headache, lightheadedness, or seizures in rare cases. The fMRI procedure is generally safe but might be uncomfortable due to loud noises and confined space.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I don't have psychiatric disorders, except maybe simple phobia, and no family history of ASD.
Select...
None of my close relatives have had hereditary neurological disorders.
Select...
I have never had a serious head injury.
Select...
I have never had a neurological disorder or neurosurgery.
Select...
I do not have any major medical conditions like cancer or heart failure.
Select...
I am not currently taking any medications for mental health or to prevent or cause seizures.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ during each fmri, up to 5 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during each fmri, up to 5 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Mentalizing Task Related (MTR) neural activity in the mentalizing network
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Typically Developing (TD): excitatory, then inhibitory, then sham rTMSExperimental Treatment2 Interventions
Participants in this group will undergo fMRI pre- and post- rTMS. Each will receive an excitatory, inhibitory and sham rTMS to the right temporoparietal junction (TPJ) on mentalizing task-related (MTR) activity over 4 study visits.
Group II: ASD: excitatory, then inhibitory, then sham rTMSExperimental Treatment2 Interventions
Participants in this group will undergo fMRI pre- and post- rTMS. Each will receive an excitatory, inhibitory and sham rTMS to the right temporoparietal junction (TPJ) on mentalizing task-related (MTR) activity over 4 study visits.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
fMRI
2019
Completed Phase 3
~1730
rTMS
2016
Completed Phase 3
~840
Find a Location
Who is running the clinical trial?
National Institute of Mental Health (NIMH)NIH
2,913 Previous Clinical Trials
2,738,455 Total Patients Enrolled
84 Trials studying Autism Spectrum Disorder
41,172 Patients Enrolled for Autism Spectrum Disorder
Yale UniversityLead Sponsor
1,920 Previous Clinical Trials
3,031,550 Total Patients Enrolled
27 Trials studying Autism Spectrum Disorder
2,357 Patients Enrolled for Autism Spectrum Disorder
Vaughn Steele, MDPrincipal InvestigatorYale University
Share this study with friends
Copy Link
Messenger